Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
Can-Fite announced the publication of a peer-reviewed article in Frontiers in Veterinary Science validating Piclidenoson for canine osteoarthritis. The study showed statistically significant improvements in mobility, pain scores, and lameness in dogs treated with Piclidenoson, with a favorable safety profile.
Key figures
- Drug Name
- Piclidenoson
- Phase Of Trial
- Phase 2
- Licensing deal value
- $325 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.